IDEXX (IDXX) Q2 2026: Instruments Drop 20%, Margin Hits 64%
IDEXX sold fewer diagnostic analyzers this quarter — instrument revenue fell 19.5% to $47.2M — and it did not matter, because the installed base did the work instead. Recurring CAG diagnostics revenue rose 11.0% to $974.7M, and consolidated gross margin reached 64.0% from 62.6%, the direct result of product cost of revenue staying flat in dollars while product revenue grew 9.3%. Operating income climbed 14.1% to $425.6M on 9.7% revenue growth, a clean demonstration of operating leverage — the tendency for profit to grow faster than sales once fixed costs are covered. For a razor-and-blades diagnostics model, a soft quarter for razors alongside accelerating blade margin is the more reassuring of the two possible outcomes.
1. Balance Sheet
1-1. Major Asset Items
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 180.1 | 196.9 | +9.3 |
| Accounts receivable, net | 552.4 | 627.1 | +13.5 |
| Inventories | 377.8 | 391.6 | +3.7 |
| Property and equipment, net | 747.4 | 733.2 | -1.9 |
| Goodwill | 414.0 | 410.9 | -0.7 |
| Intangible assets, net | 109.8 | 98.2 | -10.6 |
| Total assets | 3,350.8 | 3,442.3 | +2.7 |
Receivables grew faster than the balance sheet, but not alarmingly so. Measured against the same quarter a year earlier, receivables rose 11.9% ($560.6M at June 30, 2025) against 9.7% revenue growth. Days sales outstanding moved from 46.0 to 46.9 — a one-day slip, not a collection problem.
Inventory is the better signal. It grew 3.7% over six months while first-half revenue rose 11.8%. Inventories are stated at FIFO, not LIFO, which means the figure is directly comparable to IFRS-reporting peers. Property and equipment declined slightly despite capital spending, indicating depreciation is now running ahead of new investment.
Two line items outside the standard template deserve attention. Contract assets totaled $332.6M and capitalized consideration paid to customers $271.8M — $604.4M combined, or 17.6% of total assets, up from $562.9M at year-end. This is the balance-sheet footprint of the reagent-rental model: IDEXX funds instrument placement up front and recovers it through multi-year consumable commitments. It is the engine of the 94% CAG segment recurring mix, and it is also where the model's capital sits.
Debt maturity structure is manageable. Senior notes total $450.0M of principal at a weighted average coupon of 3.28%, of which $250.0M (55.6%) matures by March 2029 — including $75.0M in September 2026 at 3.72%. The $125.0M and $75.0M tranches due 2030 carry 2.50% coupons that will be expensive to replace. Against this, the Credit Facility's weighted average effective rate fell to 4.7% for the first half from 5.3% in 2025. Operating lease right-of-use assets of $122.8M against $127.2M of lease liabilities is a routine ASC 842 presentation and nothing more.
1-2. Liability Structure
Interest-bearing debt rose to $968.9M from $847.8M, a 14.3% increase driven almost entirely by the Credit Facility, which went from $398.0M to $519.0M. Remaining availability is $731.0M on the $1.25B facility. The sole financial covenant is a 3.5-to-1 consolidated leverage test, and the company confirms compliance.
Operating liabilities moved the other way. Accounts payable, accrued liabilities and deferred revenue totaled $651.3M versus $708.0M. The decline is concentrated in accrued employee compensation, down to $158.1M from $212.4M — the normal first-half pattern of paying out prior-year bonuses. The net picture: IDEXX borrowed to fund shareholder returns, not to fund operations.
1-3. Capital Structure
Total equity was effectively flat at $1,612.6M against $1,605.4M, despite $616.9M of net income. The reconciliation is entirely treasury stock, which grew to $(7,259.7)M from $(6,561.4)M — $698.3M of repurchases.
Retained earnings of $7,008.8M rose by exactly the net income figure, confirming no dividends; the filing states IDEXX has never paid one. Against paid-in capital of $1,921.2M, retained earnings are 3.6 times larger — earned capital, not raised capital. But cumulative treasury stock now exceeds cumulative retained earnings. IDEXX has returned more to shareholders over its history than it has retained, and book equity is consequently a poor proxy for the business's worth.
2. Income Statement
2-1. Core Metrics
| Item | Q2 2024 ($M) | Q2 2025 ($M) | Q2 2026 ($M) | 2Y CAGR |
|---|---|---|---|---|
| Revenue | 1,003.6 | 1,109.5 | 1,216.6 | +10.1% |
| Operating income | 263.8 | 373.0 | 425.6 | +27.0% |
| Operating margin (%) | 26.3 | 33.6 | 35.0 | — |
| Net income | — | 294.0 | 338.4 | — |
| Net margin (%) | — | 26.5 | 27.8 | — |
Second-quarter revenue has compounded at 8.8% annually since 2023 ($943.6M) — steady, unspectacular, and in line with a business selling into a structurally growing but not explosive end market. The margin series is less clean. Q2 2022 operating margin was 20.8% and Q2 2024 was 26.3%, both depressed relative to neighbors. Part of the explanation is litigation: IDEXX paid an approximately $80.0M royalty judgment in April 2025 that had been accrued in prior years. Single-quarter margin comparisons against 2022–2024 should be treated with care for that reason.
The operating leverage ratio this quarter was 1.46 — each 1% of revenue growth produced 1.46% of operating profit growth. On a six-month basis it was 1.21, because first-half operating expenses grew 13.5% against 11.8% revenue growth.
Diluted EPS rose 17.6% to $4.27 from $3.63. Decomposed: 15.1 points came from net income growth and roughly 2.5 points from the 2.1% reduction in diluted share count. Buybacks are contributing, but they are not carrying the quarter. The effective tax rate was 18.9% in both periods and 20.2% for both six-month periods — identical, so no tax tailwind flatters the comparison. There were no meaningful non-recurring items in operating income; a $5.0M impairment charge appears as a cash flow add-back but is not broken out in the notes.
2-2. Where the Margin Came From
The entire gross margin expansion is a product-side story, and it is stark:
| Q2 2025 ($M) | Q2 2026 ($M) | Change | |
|---|---|---|---|
| Product revenue | 657.6 | 718.6 | +9.3% |
| Cost of product revenue | 205.1 | 204.2 | -0.4% |
| Product gross margin | 68.8% | 71.6% | +2.8%p |
| Service revenue | 451.9 | 498.0 | +10.2% |
| Cost of service revenue | 209.6 | 233.3 | +11.3% |
| Service gross margin | 53.6% | 53.1% | -0.5%p |
Product cost of revenue fell in absolute dollars while product revenue grew 9.3%. That is consumables mix — VetLab consumables rose 14.7% to $430.3M — combined with the absence of lower-margin instrument hardware. Services, which is largely the reference laboratory network, remains a labor business and lost half a point of margin.
Operating expenses grew 9.9%, almost exactly in line with revenue, so they neither helped nor hurt the quarter. Within the mix, sales and marketing rose 6.3% and R&D 5.7%, both slower than revenue, while general and administrative rose 18.4%. Over six months the G&A gap is wider at +24.0% against +11.8% revenue. That is the one expense line that is not behaving, and it is worth watching.
R&D of $65.4M is 5.4% of revenue. Under US GAAP this is expensed in full with no capitalization option, which means IDEXX's reported operating margin is structurally more conservative than an IFRS peer that capitalizes development costs. Share-based compensation of $32.4M in the first half equals 1.4% of revenue — low, and a genuine quality marker.
3. Cash Flow
| Item (six months) | 1H 2025 ($M) | 1H 2026 ($M) | Change |
|---|---|---|---|
| Operating cash flow | 423.7 | 613.4 | +44.8% |
| Investing cash flow | (63.2) | (59.0) | — |
| Financing cash flow | (496.0) | (536.6) | — |
| Effect of exchange rates on cash | — | (1.0) | — |
| Ending cash | 164.6 | 196.9 | +19.6% |
Free cash flow — operating cash flow less capital expenditure — was $556.8M against $359.6M, up 54.8%. That is a 23.6% free cash flow margin.
The 44.8% jump in operating cash flow is larger than the 14.9% rise in net income, so it needs unpacking. Two prior-year drags explain most of it. The $80.0M litigation judgment was paid in April 2025, hitting 2025 cash flow without touching 2025 earnings, since it had been accrued earlier. And cash taxes paid fell to $107.1M from $137.4M. Together those account for roughly $110M of the $189.7M improvement. The rest is a smaller working capital drag: "other assets and liabilities" consumed $66.5M versus $133.5M.
Earnings quality is now clean. Operating cash flow to net income was 0.99 for the first half, against 0.79 a year earlier. The prior-year reading was distorted by the judgment payment, not by receivables quality, and the recovery to roughly 1.0 is the expected state for this business.
Capital intensity is falling. Capital expenditure of $56.6M is 2.4% of revenue, down from 3.0%. At that level, with property and equipment declining, spending looks closer to maintenance than expansion.
The financing side is where the tension sits. IDEXX spent $697.8M on buybacks against $556.8M of free cash flow — a $141.0M gap, bridged by $121.0M of net revolver borrowing and $51.1M of option exercise proceeds. It repurchased 1.17 million shares in the open market at an average $592.41, against 1.64 million at $448.02 a year earlier. Fewer shares at a 32.2% higher price at a lower total outlay.
4. What Else Matters
The recurring base is still tightening. Recurring revenue — CAG diagnostics recurring plus veterinary software recurring — was 94.0% of CAG segment revenue, up from 92.6%. In a quarter when instrument placements fell, recurring revenue grew 11.0%. That is the whole investment case for this model working as designed.
The instrument decline is mostly a comparison artifact. CAG instrument revenue fell 19.5% in Q2 but only 1.1% over six months. Backing into the first quarter, instrument revenue was $42.4M versus $32.0M — up 32.5%. Placement timing shifted between quarters; the half-year trend is flat, not collapsing. Flat instrument placement is still worth monitoring, because today's placements are tomorrow's consumables, but a single quarter says little.
The smaller segments are outperforming on margin. Water revenue rose 14.8% with gross margin expanding to 74.4% from 69.6%. LPD revenue rose 10.8% with gross margin jumping to 53.0% from 47.0%. Together they are only 7.7% of revenue, but both delivered gross profit growth above 22% — faster than CAG's 11.5%.
Rapid assay is the soft spot. Rapid assay products grew 1.3% to $101.6M, and CAG diagnostics services and accessories 3.2%. These are the parts of the recurring base that are not growing, and they are being carried by VetLab consumables and reference laboratory services.
Contingent liabilities are quiet. The filing states litigation accruals were "not material" as of June 30, 2026, and the royalty judgment that dominated prior years was settled and released in April 2025. No "reasonably possible" exposure is flagged. Guarantees and indemnifications carry no recorded liability.
Currency is a live but hedged exposure. Foreign currency translation reduced other comprehensive income by $11.9M in the first half, reversing a $61.1M gain a year earlier. Hedge positions moved the other way, adding $17.2M. Accumulated other comprehensive loss narrowed to $(63.5)M from $(68.8)M. The company hedges euro, sterling, yen, Canadian dollar and Australian dollar exposure.
5. Takeaways
What grew. Margin, more than volume. Revenue growth of 9.7% is respectable; the 1.4-point gross margin expansion and 1.4-point operating margin expansion are what turned it into 17.6% EPS growth. The mechanism is specific and repeatable while mix holds: consumables growing 14.7% against flat product costs.
What the risks are. Three. First, instrument placements — a genuinely flat year of placements eventually slows consumable growth, and the six-month figure is flat. Second, G&A growing 24.0% in the first half against 11.8% revenue growth; if that persists it will consume the gross margin gain. Third, the capital structure — debt rose 14.3% in six months to fund repurchases, and $200.0M of 2.50%-coupon notes due 2030 will be expensive to refinance into a higher rate environment.
Capital allocation. Unambiguous and unchanged: no dividend, minimal M&A (a single $15.6M customer-relationship asset purchase in September 2025), capital expenditure held at 2.4% of revenue, and everything else into buybacks. IDEXX
